Characteristics of immune memory 10–15 years after primary hepatitis B vaccination by Brunskole Hummel, Irena et al.
This article appeared in a journal published by Elsevier. The attached
copy is furnished to the author for internal non-commercial research
and education use, including for instruction at the authors institution
and sharing with colleagues.
Other uses, including reproduction and distribution, or selling or
licensing copies, or posting to personal, institutional or third party
websites are prohibited.
In most cases authors are permitted to post their version of the
article (e.g. in Word or Tex form) to their personal website or
institutional repository. Authors requiring further information
regarding Elsevier’s archiving and manuscript policies are
encouraged to visit:
http://www.elsevier.com/authorsrights
Author's personal copy
Vaccine 34 (2016) 636–642
Contents lists available at ScienceDirect
Vaccine
j o ur na l ho me  page: www.elsev ier .com/ locate /vacc ine
Characteristics  of  immune  memory  10–15  years  after  primary
hepatitis  B  vaccination
Irena  Brunskole  Hummela,∗, Anita  Zitzmanna, Monika  Erla, Jürgen  J.  Wenzelb,
Wolfgang  Jilga
a Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany
b Institute of Clinical Microbiology and Hygiene, University Medical Centre Regensburg, 93053 Regensburg, Germany
a  r  t  i  c  l e  i  n  f  o
Article history:
Received 29 July 2015
Received in revised form 8 November 2015
Accepted 11 December 2015
Available online 21 December 2015
Keywords:
Hepatitis B vaccination
Immune memory
Kinetics
Anti-HBs titre
Cellular immunity
ELISpot
a  b  s  t  r  a  c  t
Background  and  aims:  The  deﬁnition  of  immune  memory  after  hepatitis  B vaccination  is still  under
debate.  Therefore,  we  analysed  hepatitis  B surface  antigen  (HBsAg)-speciﬁc  memory  in more  detail  by
investigating  the kinetics  of  humoral  and  cellular  responses  after  hepatitis  B booster  vaccination.
Methods:  The  anti-HBs  kinetics  of  23  individuals  with  anti-HBs  titres  below  10 IU/l,  who  had  been  vacci-
nated  10–15  years  ago,  was  monitored  at day  0,  3,  7, 14  and  28  after booster  vaccination.  HBsAg-speciﬁc
IFN-  and  IL5-secreting  cells  in  enriched  CD4+ fraction  were  measured  at day  0,  7  and  28 post-booster
by  enzyme-linked  immunospot  assay  (ELISpot).
Results: 22 of 23  subjects  showed  similar  anti-HBs  kinetic  curves,  including  3 of  4 subjects  who  did  not
reach  anti-HBs  titres  of 10  IU/l. The  steep  anti-HBs  increase  started  between  day  3 and 7 and  peaked
around  day  14.  A  plateau  or only  minimal  changes  were  visible  between  day  14 and  28.  17.4% of  subjects
showed  pre-booster  cellular  responses,  and  this  rate  had increased  to 47.8%  and  56.5% after  7  and  28  days,
respectively.  The  kinetic  patterns  of  T cell  responses  differed  considerably  among  subjects.  A  dominance
of  Th2  responses  (IL5 secretion)  over  Th1 responses  (IFN  secretion)  could  be  observed.
Conclusions:  The  presence  of  B cell  memory  could  be  shown  by a  typical  anamnestic  anti-HBs  response
curve  after  a booster  dose  in  all  but  one  individual.  In contrast,  T cell responses  to  booster  vaccination,
which  occurred  in approximately  50%  of  participants,  were  rather  heterogeneous.
© 2015  Elsevier  Ltd.  All  rights  reserved.
1. Introduction
Protection after hepatitis B vaccination is based on two immune
mechanisms: speciﬁc antibodies against hepatitis B surface anti-
gen (HBsAg) confer protection against infection with the hepatitis B
virus (HBV), whereas HBsAg-speciﬁc B and T cell-mediated immune
memory protects against HBV-disease after the disappearance of
Abbreviations: ELISpot, enzyme-linked immunospot assay; HBsAg, hepatitis B
surface antigen; HBV, hepatitis B virus; IFN, interferon ; IL5, interleukin 5; PBMC,
peripheral blood mononuclear cells; SFC, spot forming cells; Th1, T helper 1; Th2, T
helper 2.
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antibodies [1]. HBsAg-speciﬁc immune memory is usually shown
by an anamnestic response to a booster dose of hepatitis B vac-
cine. A typical anamnestic response is characterised by a rapid
10–100-fold increase in speciﬁc antibodies, which starts 5–8 days
after the re-exposure to the antigen and peaks after about 14 days
[2–4]. HBsAg-speciﬁc memory has been shown to persist for at
least 15–17 years after immunisation [5–7]. Long-term follow-up
studies have shown that clinical HBV-disease or HBsAg-carrier sta-
tus rarely occur among successfully vaccinated individuals, even in
the case of anti-HBs titres <10 IU/l [8]. These observations led to
the conclusion that protection against clinically signiﬁcant break-
through infection and chronic carriage is long-term rendering
booster doses unnecessary [1,9–11]. However, over the past years,
a number of studies have reported about waning immunity over
time by showing a loss of the ability to respond to booster vaccina-
tion [12–16]. A recent meta-analysis has shown that, 20 years after
infant vaccination, about 40% of individuals who  had lost protecting
antibodies did not respond to booster vaccination [17].
However, one problem in evaluating studies reporting on wan-
ing immunity is the lack of a clear deﬁnition of immune memory.
http://dx.doi.org/10.1016/j.vaccine.2015.12.033
0264-410X/© 2015 Elsevier Ltd. All rights reserved.
Author's personal copy
I. Brunskole Hummel et al. / Vaccine 34 (2016) 636–642 637
Anti-HBs antibodies can be reliably measured by standardised tests,
but no standardised method is yet available for measuring spe-
ciﬁc immune memory. In studies in which immune memory was
shown by means of the increase in anti-HBs after booster vacci-
nation, anti-HBs titres were mostly measured only once and at
rather different time points, ranging from 10 days to 2 months
post-booster [7,18–21]. In addition, in some studies anamnes-
tic response was deﬁned as an increase in anti-HBs to ≥10 IU/l
[21–25], in other studies as 4-fold increase in anti-HBs [5], and
sometimes both criteria were applied [13,15,20,26]. Because of
the differing deﬁnitions, it seems to be impossible to differenti-
ate in all cases between anamnestic responses due to the presence
of immune memory and primary responses after loss of immune
memory.
In contrast to B cell memory, T cell memory has only been inves-
tigated in a few studies. In most of these few studies speciﬁc T cells
were analysed after HBV booster vaccination using ELISpot assays
with unfractionated PBMCs (peripheral blood mononuclear cells).
However, this method is prone to failure because of the possible
activation of nonspeciﬁc bystander cells. Moreover, HBsAg-speciﬁc
T cell memory has been rather heterogeneously analysed in these
studies and measured at different time points after booster vacci-
nation [12,27–29].
In the present study we aimed to deﬁne optimal criteria for
assessing HBsAg-speciﬁc immune memory. To assess B cell mem-
ory, we studied the kinetics of anti-HBs titres at day 0, 3, 7, 14 and
28 post-booster in subjects who had been vaccinated 10–15 years
before and in whom anti-HBs had fallen below the critical value of
10 IU/l. In order to analyse the T cell memory as well, we  enriched
CD4+ T cells and identiﬁed HBsAg-speciﬁc T helper 1 (Th1) and T
helper 2 (Th2) cell responses in this fraction by measuring IFN-
and IL5-secreting cells at day 0, 7 and 28 post-booster.
2. Methods
2.1. Study cohort
77 adolescents (33 male, 44 female) aged 14–18 years were
included in this study. All subjects had obtained a full course of
3 vaccinations against hepatitis B 10–15 years ago. The interval
between the 1st and the 2nd dose was 1–3 months (mean 1.4
months) and between the 2nd and the 3rd dose 6–20 months (mean
11.7 months). 66 subjects had received monovalent vaccines (63
Engerix B®, 3 GenHBvax®), 1 subject the hepatitis A/B combination
vaccine Twinrix® and 1 the hexavalent vaccine Hexavac®. In 3 sub-
jects, Engerix B® and GenHBvax® were mixed and in 6 subjects, the
brand of at least one vaccine was unknown.
Anti-HBs and anti-HBc were determined using commercial
enzyme immunoassays on the Architect System (Abbott, Sligo,
Ireland). Subjects with anti-HBs values <10 IU/l were offered a
single booster dose of monovalent Hepatitis B vaccine (Engerix
B®, GSK, Rixensart, Belgium). The anti-HBs titre of revaccinated
subjects was determined at day 0, 3, 7, 14 and 28 post-booster.
Additionally, cellular immune responses were analysed by ELISpot
at day 0, 7 and 28. Healthy non-vaccinated volunteers were studied
as controls.
Written informed consent was obtained from each subject and
at least one parent before enrolment in this study. The study pro-
tocol had been approved by the Ethics Committee of the University
Regensburg before the study start (vote number 10-101-0166).
2.2. Isolation of CD4+ T cells
PBMCs were isolated from heparinised blood on density gradi-
ents (Pancoll human, PAN Biotech, Aidenbach, Germany) and stored
in liquid nitrogen until used. CD4+ T cells were isolated from PBMCs
by negative selection using magnetic cell sorting (CD4+ T cell isola-
tion kit, Miltenyi Biotech, Bergisch-Gladbach, Germany). Purity of
the enriched CD4+ fraction was assessed by ﬂow cytometry using
anti-CD3-VioBlue and anti-CD4(VIT4)-PerCP (Miltenyi) and usually
exceeded 85%. Fewer than 3% of CD3+CD4+ cells were normally
found in the CD4-free cell fraction. Propidium iodide (Miltenyi) was
used for exclusion of dead cells.
Flow cytometric analyses were done with FACS Canto II (BD Bio-
sciences, San Diego, CA). Data were analysed with FlowJo software
Version X.0.7 (Tree Star, Ashland, OR, USA).
2.3. Detection of IFN- and IL5-secreting cells by ELISpot
ELISpot assays were conducted using the FluoroSpot kit for
Human IFN/IL-5 (Mabtech, Nacka Strand, Sweden) according to
the manufacturer’s instructions [30,31]. A mixture of 54 peptides
(15-mer with 11 amino acid overlap, purity ≥90%, JPT, Berlin,
Germany), which covered the entire sequence of the small HBsAg
[32], was used for 44 h-stimulation in a ﬁnal concentration of
2 g/ml per peptide. Routinely, each sample was  analysed in 5
replicates. In 8% (22 of 276 cases), fewer replicates were tested
because of the insufﬁcient amount of PBMCs available (2 replicates
in 1%, 3 replicates in 1%, 4 replicates in 6%). Cells stimulated with
5 g/ml phytohaemagglutinin (Biochrom, Berlin, Germany) were
tested in duplicates as a positive control. Anti-CD28 was added
to each well at a ﬁnal concentration of 0.1 g/ml. Each well con-
tained 0.16% of dimethyl sulfoxide. Spots were counted with an AID
ELISpot Reader (Advanced Imaging Devices, Straßberg, Germany).
2.4. Deﬁnition of positive cellular responses
Spot forming cells (SFC) were determined in parallel for every
sample in the following four setups:
(A) 2 × 105 cells of CD4+ fraction and 1 × 105 cells of CD4-free frac-
tion (needed for antigen presentation) without HBsAg peptides,
(B) 2 × 105 cells of CD4+ fraction and 1 × 105 cells of CD4-free frac-
tion with HBsAg peptides,
(C) 1 × 105 cells of CD4-free fraction without HBsAg peptides, and
(D) 1 × 105 cells of CD4-free fraction with HBsAg peptides.
The number of HBsAg-induced SFC/well was  calculated for fur-
ther data analysis as follows: (mean B − mean A) − (mean D − mean
C).
Cellular immune responses in revaccinated subjects were
deﬁned as positive (HBsAg-speciﬁc) when:
(a) the number of SFC in setup B was ≥2-fold higher than the num-
ber of SFC in setup A and
(b) the number of HBsAg-induced SFC calculated as mentioned
above was ≥4.0 for IL5-secretion and ≥5.2 for IFN-secretion
(≥mean + 2 SD of the number of SFC measured in 9 non-
vaccinated subjects).
2.5. Statistical analysis
Statistical analysis was  done with GraphPad Prism 6.02 (Graph-
Pad Software, LA Jolla, CA). Two-sided p values of <0.05 were
considered signiﬁcant. Anti-HBs values <0.1 IU/l were set to 0.1 IU/l
for further data analysis.
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Fig. 1. Kinetics of anti-HBs response to hepatitis B booster vaccination. Kinetics of an anti-HBs response after booster in 23 study subjects with pre-booster anti-HBs-levels
<1  IU/l (A), between 1 and 5 IU/l (B) and between 5 and 10 IU/l (C).
3. Results
3.1. Serological results 10–15 years after primary hepatitis B
vaccination
All 77 participants were anti-HBc negative 10–15 years after
primary immunisation. 51 subjects (66.2%) showed anti-HBs con-
centrations ≥10 IU/l (10–646 IU/l, median 52 IU/l). In 19 (24.7%), the
anti-HBs titre was ≥100 IU/l. No correlation was found between the
immunisation schedule (especially the interval between the 2nd
and the 3rd dose) of primary vaccination and the anti-HBs levels
10–15 years later.
26 subjects (33.8%) had an anti-HBs titre <10 IU/l, of whom 21
had been vaccinated in infancy with Engerix B®, 2 with GenHBvax®,
1 with Twinrix® and 1 with Hexavac®. In 1 subject, the brand of the
vaccine was unknown.
3.2. Anti-HBs response in revaccinated subjects
23 subjects with anti-HBs <10 IU/l were revaccinated, and
anti-HBs responses were assessed at day 0, 3, 7, 14 and 28 post-
booster (Figs. 1 and 2). The ﬁrst response was detected at day
7 (1 subject showed an increase from 9.3 to 10.0 IU/l at day 3,
which was not considered signiﬁcant). At day 7, anti-HBs had
increased above 10 IU/l in 11 subjects, at day 14 in 17 subjects and
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Fig. 2. Number (%) of subjects with anti-HBs ≥10 IU/l at different time points after
booster vaccination.
at day 28 in 2 additional subjects (Fig. 2). 12 subjects showed the
highest anti-HBs titre at day 14 and 11 subjects at day 28. At the
latter time point, 82.6% of participants had developed anti-HBs
concentrations of ≥10 IU/l, 65.2% of ≥100 IU/l, 34.8% of ≥1000 IU/l
and 8.7% of ≥10,000 IU/l.
A signiﬁcant correlation was found between the anti-HBs titres
pre-booster and 28 days post-booster (p = 0.006, Pearson’s cor-
relation analysis, supplementary Fig. 1). 6 of 9 subjects with a
pre-booster anti-HBs titre <1.0 IU/l showed very poor responses
(Fig. 1A). All subjects with pre-booster values between 5 and
10 IU/l had developed anti-HBs responses of ≥100 IU/l 4 weeks
after booster vaccination (Fig. 1C). Again, there was no correlation
between the response to the revaccination and the vaccine or the
immunisation schedule used for the primary vaccination.
3.3. Cellular immune response in revaccinated subjects
HBsAg-speciﬁc cellular responses are shown in Table 1 and
Fig. 3. 4 participants (17.4%) had positive pre-booster cellular
responses. At day 7 post-booster, 11 participants (47.8%) showed
speciﬁc cells, and, at day 28, the number of positive subjects had
increased to 13 (56.5%). The frequency of IL5-producing cells per
subject rose from a mean of 17 SFC/2 × 105 CD4+ T cells (range
0–123) at day 7 to a mean of 33 SFC/2 × 105 CD4+ T cells (range
0–232) at day 28; the corresponding numbers for IFN-secreting
cells at day 7 and 28 were 8.7 SFC/2 × 105 CD4+ T cells (range
0–63) and 20 SFC/2 × 105 CD4+ T cells (range 0–317), respectively.
In 1 subject, the number of IL5-secreting cells remained stable at
the high level of about 55 SFC/2 × 105 CD4+ T cells at all three
time points measured (Fig. 3B). The number of subjects with IL5-
secreting cells was clearly higher than that of IFN-secreting cells
(12 vs. 8 at day 28). A signiﬁcant positive correlation could be found
between IL5- and IFN-secreting SFC (p < 0.001, Spearman’s rank
correlation analysis, supplementary Fig. 2).
The calculation of mean fold changes at day 7 and 28 post-
booster by using pre-booster responses as a baseline showed
distinct kinetic proﬁles for IL5 and IFN secretion (Fig. 4). The mean
fold change for IL5 secretion showed a relatively slow and steady
increase from day 0 to day 28, whereas the mean fold change of
IFN secretion increased steeply from day 0 to day 7, levelling off
between day 7 and 28.
Looking for a relationship between anti-HBs values and
T cell responses, we did not ﬁnd any correlation between
Author's personal copy
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Table  1
Hepatitis B surface antigen-speciﬁc IL5- and IFN-secreting cells after hepatitis B booster, 10–15 years after primary vaccination, determined by ELISpot.
Response after
booster
Negative Overall
positiveb
Weakly positiveb (<10
SFC)
Moderately positiveb
(10–30 SFC)
Strongly positiveb
(>30 SFC)
IL5a Day 0 20 (86.9) 3 (13.1) 0 2 (8.7) 1 (4.4)
Day  7 14 (60.9) 9 (39.1) 2 (8.7) 3 (13.0) 4 (17.4)
Day  28 11 (47.8) 12 (52.2) 2 (8.7) 4 (17.4) 6 (26.1)
IFNa Day 0 21 (91.3) 2 (8.7) 2 (8.7) 0 0
Day  7 18 (78.2) 5 (21.7) 2 (8.7) 1 (4.4) 2 (8.7)
Day  28 15 (65.2) 8 (34.8) 4 (17.4) 2 (8.7) 2 (8.7)
IL5  and IFNa Day 0 22 (95.6) 1 (4.4) – – –
Day  7 20 (87.0) 3 (13.0) – – –
Day  28 16 (69.6) 7 (30.4) – – –
IL5  and/or IFNa Day 0 19 (82.6) 4 (17.4) – – –
Day  7 12 (52.2) 11 (47.8) – – –
Day  28 10 (43.5) 13 (56.5) – – –
a Data are number (%) of revaccinated subjects.
b Criteria for a positive response are described in Section 2.4.
post-booster anti-HBs titres and IL5-secreting SFC (p = 0.074, Spear-
man’s rank correlation analysis, Fig. 5A), but the post-booster
anti-HBs titres positively correlated to the number of IFN-
secreting SFC (p = 0.002, Fig. 5B). Interestingly, 3 participants
showed a relatively strong IL5 response (15, 20 and 57 SFC/2 × 105
CD4+ T cells) after booster vaccination whereas their anti-HBs titres
remained below 10 IU/l.
No correlation could be found between vaccination history and
the quality of cellular responses after the booster dose.
4. Discussion
Immune memory is the crucial mechanism which establishes
long-term protection after hepatitis B vaccination. It is particularly
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important in individuals vaccinated in early infancy, because in
many of them neutralising antibodies decline below the protecting
level of 10 IU/l within 10–15 years [17]. Hepatitis B speciﬁc immune
memory has been described in several papers [12,29,33,34], but
no consensus on a clear deﬁnition of immune memory has yet
been found. To characterise immune memory in more detail, we
analysed the kinetics of humoral and cellular responses to a chal-
lenge with hepatitis B vaccine in adolescents who had lost their
protecting antibodies 10–15 years after infant vaccination.
19 (82.6%) of our 23 revaccinated subjects reached anti-HBs lev-
els of ≥10 IU/l. All subjects showed a typical anamnestic response
curve as similarly demonstrated earlier for tetanus and pertussis
vaccine [2,4]: a steep increase in anti-HBs, which started between
day 3 and 7, reached a peak around day 14, and showed a plateau
or only minimal changes between day 14 and 28. Interestingly, 3
of 4 subjects with anti-HBs <10 IU/l also showed similar kinetics.
Thus, it may  be assumed that the shape of the curve is deﬁned
solely by the response of memory B cells irrespective of their fre-
quency, which, on the other hand, is responsible for the resulting
antibody level. A correlation between serum antibody levels and
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secreting spot forming cells (SFC)/2 × 105 CD4+ T cells (A) and between anti-HBs
titres and IFN-secreting SFC/2 × 105 CD4+ T cells (B) are shown. r – Spearman’s
rank  correlation coefﬁcient.
the frequency of corresponding IgG memory B cells was already
shown by Bernasconi et al. for tetanus toxoid and measles virus [2].
According to our ﬁndings, peak anti-HBs values are usually
reached between day 14 and 28 after booster vaccination. Con-
sequently, no large differences should be found among studies
measuring response between day 14 and 28 after booster vacci-
nation [10,13,20,22,23].
In contrast to B-cell memory, which can easily be studied
by means of standard anti-HBs assays, T-cell memory has to be
assessed by direct analysis of T cells. First, this is complicated by
the fact that the absolute number of speciﬁc T cells in peripheral
blood is very low. Secondly, the most common method for monitor-
ing T cell responses is the ELISpot, which is probably also the most
sensitive assay. However, when this test is performed with unfrac-
tionated PBMCs, which is very often the case, its speciﬁcity may  be
impaired by the fact that bystander cells may  also non-speciﬁcally
produce cytokines. Finally, no standardised criteria exist for inter-
preting ELISpot results (applying more or less stringent criteria can
drastically inﬂuence study results).
To overcome these problems at least partially, we used enriched
CD4+ T cells and analysed CD4-free cell fraction in parallel to detect
non-speciﬁcally induced cells [35]. Moreover, to deﬁne a positive
result, we used external and internal controls, which increased the
speciﬁcity of our assay but probably at the expense of its sensitivity.
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Before revaccination, 17.4% of our participants showed HBsAg-
speciﬁc CD4+ T cells. This rate had increased to 47.8% at day 7 and
to 56.5% at day 28 after challenge. These numbers were substan-
tially lower than those found in a similar study with adults [36], in
which the cellular responses of each of the 15 subjects were already
detectable before booster vaccination. However, these differences
may  have several reasons. First, in the latter study, CD4+ cells were
further separated into effector and memory cells, which increased
the sensitivity of the test. Moreover, speciﬁc T cell responses may
disappear over time after vaccination; the interval of 4–8 years
between vaccination and evaluation was considerably shorter than
that of 10–15 years in the present study. Finally, individuals vacci-
nated as adults preferentially show a dominance of Th1 cells [36,37]
in contrast to the dominance of Th2 cells in newborns and infants
[12,38], as evident also from the present study. Such age-dependent
immune characteristics may  also be responsible for our observa-
tion that T cell responses after challenge were more frequently
detected at day 28 in contrast to responses of subjects vaccinated as
adults, which peaked at day 10 [36]. Similar age-dependent kinetic
patterns have already been observed for cellular responses after
inﬂuenza vaccination [39].
A study more suitable for a comparison with our investigation
was conducted in Taiwan, in which 92 subjects were tested 15–18
years after neonatal immunisation [12]. The authors found spe-
ciﬁc T cells in 34.8% of subjects before challenge and in 72.8% 28
days afterwards. The reason for our lower values is most proba-
bly the lower sensitivity of our assay as mentioned above. In two
other studies with young adults conducted 18–20 years [29] and
20 years [28] after neonatal vaccination, T cell immunity was also
analysed by IFN ELISpot. In the study by Chinchai et al., 50.6%
of subjects showed a speciﬁc response without any booster [29],
and in the study by Zhu et al., 93.2% 10–12 days after booster [28].
However, both studies were conducted in populations at a high
risk for hepatitis B. In the study by Zhu et al. [28], 88.6% of subjects
also had detectable HBeAg-speciﬁc cellular immunity. Thus, cellu-
lar reaction to HBsAg in that study and probably also in the study
by Chinchai et al. [29] could be the result of HBV contact rather than
of vaccination.
Our study gives a detailed insight into the kinetics of HBsAg-
speciﬁc Th1 and Th2 cell responses, which were found to be rather
heterogeneous. By analysing mean fold changes of SFC (Fig. 4), we
could observe divergence in the kinetics of IL5- and IFN-secretion.
However, focusing on the absolute number of HBsAg-speciﬁc cells,
we observed an increase in about 80% of subjects between day 7 and
28 post-booster, irrespective of the cytokine analysed. Therefore,
although effector memory T cells can be recruited within hours to
days after antigen re-encounter [40], it seems to make sense to
monitor HBsAg-dependent cellular immunity at a later time point,
when also secondary effector T cells are already detectable, which
were generated by the activation of central memory T cells.
In conclusion, T cell memory responses, detected in only about
50% of revaccinated adolescents, showed heterogeneous kinetic
courses. In contrast, B cell memory was found by typical anamnestic
anti-HBs response curves in almost all subjects, also in those with
post-booster anti-HBs titres <10 IU/l. However, if immune memory
still mediates protection in these individuals needs to be further
investigated.
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